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Preface 
 
Proteins play important roles in living organisms. Therefore, elucidation of these protein 
functions is an important task for understanding the biological profiles of these 
organisms. Notably, the elucidation of functions of a wide variety of proteins in protein 
mixtures (proteomes) is of great importance for understanding vital phenomena, 
because proteins work within proteomes. Tracing the dynamic behavior of proteins in 
cells leads to a powerful tool for elucidating biological functions of proteins, in which 
attachment of reporter molecules such as fluorescent dyes on proteins of interest is 
needed.
1
 The ligand-dependent incorporation of a reporter onto the target protein using 
affinity-based labeling systems has thus emerged as an important strategy (Figure 1).
2,3
 
In this strategy, generally used reagents are composed of three functional units, namely 
(1) a ligand unit for the selective interaction with a target protein; (2) a reporter unit for 
the visualization of a target protein; (3) a reactive unit for the covalent attachment of the 
reporter unit to a target protein. Because the conventional labeling reagents have a 
slightly activated reactive unit, there is a potential risk of a non-target protein being 
labeled by the activated reagent in a ligand-independent manner. Therefore, it was 
envisaged that the activation of labeling reagents through interaction between a target 
protein and its ligand could potentially overcome the problems associated with 
conventional labeling reagents. With this in mind, I attempted to adapt 
N-sulfanylethylanilide (SEAlide) unit developed by our group as reactive unit of a 
labeling reagent. 
In Chapter 1, design and synthesis of SEAL-tag is described. The application of 
SEAL-tag for selective labeling of human carbonic anhydrase (hCA) and 
cyclooxygenase 1 (COX-1) is reported in Chapter 2. 
2 
 
 
Figure 1. Selective labeling of a target protein using an affinity-based labeling method. 
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Chapter 1 Development of SEAlide-based labeling tag (SEAL-tag)  
 
1.1 Background 
 
Affinity-based protein labeling has recently attracted considerable attention as an 
efficient strategy for introduction of a reporter unit (e.g., fluorescent dyes or biotin) onto 
target proteins of bioactive compounds. In this method, employed affinity-based 
labeling reagents are generally composed of three functional units, including (1) a 
ligand unit for the selective recognition of a target protein; (2) a reporter unit for the 
visualization of the labeled protein; and (3) a reactive unit for a covalent installation of 
the reporter units onto the target protein. 
Recently, Hamachi and co-workers developed several labeling reagents based on 
ligand-directed tosyl (LDT) chemistry (Figure 2a)
4
 and ligand-directed acyl imidazole 
(LDAI) chemistry (Figure 2b).
5
 An LDT reagent bearing phenylsulfonate as a reactive 
unit was applied to label several target proteins, such as carbonic anhydrase (CA) and 
FK506-binding protein (FKBP12), and an LDAI reagent bearing acyl imidazole as a 
reactive unit was applied to modify target proteins such as dihydrofolate reductase 
(DHFR) and a membrane-bound folate receptor (FR). Additionally, Sodeoka’s group 
developed a labeling reagent bearing O-nitrobenzoxadiazole (O-NBD) unit as reactive 
unit, with the reagent employed for selective labeling of a partner protein of translocator 
protein (TSPO), voltage-dependent anion channel (Figure 2c).
6
  
 
4 
 
 
 
 
 
 
Figure 2. Schematic illustrations of protein labeling methods. (a) Ligand-directed 
tosylate (LDT) chemistry developed by Hamachi’s group. (b) Ligand-directed acyl 
imidazole (LDAI) chemistry developed by Hamachi’s group. (c) O-NBD method 
developed by Sodeoka’s group. 
 
(b) 
(c) 
(a) 
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However, the reactive units of such labeling reagents were slightly and constitutively 
activated, which sometimes resulted in the labeling of non-target proteins in a 
ligand-independent manner. Some groups carefully examined reactivity against 
non-targets and demonstrated stability of their labeling reagents under physiological 
conditions.
4(c),7
 Although such labeling of non-targets with the activated reagent has 
been documented to be mostly not significant, it has been considered that an 
unprecedented labeling reagent that remains inert in the absence of targets, but is 
activated upon its binding to targets, would be ideal for the protein labeling (Figure 3). 
In this context, the chemical basis of the SEAlide involved in native chemical ligation 
(NCL) was considered to enable the development of this unprecedented reagent. 
 
 
 
Figure 3. Selective labeling of a target protein by an affinity-based labeling reagent 
activated by binding to targets. 
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The SEAlide was developed as a crypto-thioester by our group and has been 
successfully applied to the chemical synthesis of proteins, being used in a one-pot/N– 
to–C-directed sequential NCL reaction (Scheme 1).8,9  
 
 
 
Scheme 1. SEAlide peptide as a potential peptide thioester equivalent. 
 
 
The NCL, which features the chemoselective coupling of peptide thioesters with 
N-terminal cysteinyl peptide, is among the most reliable fragment-coupling reactions 
(Scheme 2).
10
 
 
 
 
  
 
Scheme 2. Reaction mechanism of native chemical ligation. 
7 
 
The SEAlide unit generally remains electrophilically inert as the amide-form under 
neutral conditions; however, participation of the SEAlide unit in the NCL reaction 
requires the conversion of the amide-form to the corresponding thioester form as an 
electrophilically active species. Our research on the SEAlide, involving its use in 
chemical synthesis of proteins, has disclosed that the unreactive amide-type SEAlide 
could be easily converted to the reactive thioester-type SEAlide and participate in NCL 
reaction only in the presence of phosphate salts under neutral conditions. Our 
unexpected finding suggested that phosphate salts could function as a general acid-base 
catalyst for the intramolecular N–S acyl transfer, promoting the reaction of the SEAlide 
with nucleophiles such as the N-terminal cysteinyl residue (Scheme 3).
9(f)
 I thus 
envisioned that the unprecedented labeling reagent could be developed on the basis of 
the unique nature of the SEAlide. 
 
 
 
Scheme 3. Potential involvement of phosphate salts in N–S acyl transfer in SEAlide 
unit. 
 
 
Incidentally, protein surfaces are composed of various polar functional groups, 
including hydroxyl, amino, carboxyl, imidazole, and guanidine groups. The cluster of 
functional groups could cooperatively work as general acid-base catalysts, potentially 
promoting the N–S acyl transfer of the SEAlide unit. With this in mind, I hypothesized 
that the immobilization of the stable amide-type SEAlide on protein surfaces could 
induce the activation of the SEAlide to the corresponding thioester through N–S acyl 
transfer. The generated electrophilically active thioester part could potentially behave as 
the reactive unit of affinity-based labeling reagents. Based on my hypothesis, a 
SEAlide-based labeling tag (SEAL-tag) bearing the SEAlide unit as the reactive unit of 
the labeling reagent was designed. Without interacting with target proteins, the 
8 
 
SEAL-tag would remain inert as its amide form. This would therefore prevent the 
SEAL-tag from reacting with non-targets, because it would not be efficiently 
concentrated on the protein surface, which would be required as an acid-base catalyst. 
On the other hand, the specific binding of the SEAL-tag with the target protein via 
interaction between the ligand and the target would allow the labeling reagent to be 
concentrated on the target protein for a certain period, with the cluster of functional 
groups on the target protein working as general acid-base catalysts. This would 
therefore result in the N–S-acyl-transfer of SEAlide followed by acylation of the 
nucleophilic residues on the target protein in a ligand-dependent manner (Scheme 4). 
Based on my hypothesis, I prepared unreactive amide-type SEAL-tags and applied 
SEAL-tags to label two model proteins, human carbonic anhydrase (hCA) and 
cyclooxygenase 1 (COX-1). 
 
 
 
 
Scheme 4. Strategy for the selective labeling of a target protein using SEAL-tag. 
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1. 2 Molecular design and synthesis of the SEAL-tag 
 
The incorporation of an S-protected SEAlide unit as a stable synthetic intermediate 
enabled the desired SEAL-tags to be readily prepared using standard Fmoc-based 
solid-phase protocols, representing a considerable advantage over other techniques 
generally used for the synthesis of labeling reagents. 
General structures of SEAL-tags are shown in Figure 4. In this study, I chose hCA and 
COX-1 as model target proteins of bioactive compounds. The cytosolic protein hCA 
participates in several biological processes, including regulation of pH, transportation of 
CO2 and HCO3
-
, and balance of water and electrolyte.
11
 Because (1) Co-crystal 
structures of hCA–benzenesulfonamide (SA) derivatives have been previously 
reported;
12
 (2) ethoxyzolamide (EZA), which is a strong binder against the SA-binding 
pocket of hCA,
13
 can be readily obtained from commercial sources, I selected hCA as 
one of the model target proteins and SA, as a specific ligand of hCA, was chosen and 
used as the ligand unit of SEAL-tag.  
Cyclooxygenase, involved in the biosynthesis of prostaglandins from arachidonic acid 
(AA), was selected as the second model target protein.
14
 Because non-steroidal 
anti-inflammatory drugs (NSAIDs) such as indomethacin or ibuprofen inhibit the 
COX-1 mediated synthesis of prostaglandins,
15
 competitively binding to the active site 
of COXs, the indomethacin was chosen as the ligand and introduced into the SEAL-tag.  
A fluorescein-thiocarbamoyl (FTC) group or biotin was introduced as the reporter into 
SEAL-tag, because FTC or biotin-modified protein is easily detected by fluorescence 
gel imaging (FI) or Western blotting using streptavidin-HRP, respectively. In addition, 
flexible ethylene glycol (mini-PEG) linkers of various lengths were also embedded into 
the reagents in consideration of reactivity property of the SEAL-tags with targets and 
their solubility in aqueous environments. 
4(d),16
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Figure 4. Structure of SEAL-tags. 
 
 
Our synthetic strategy of SEAL-tag for labeling of hCA is shown in Scheme 6. First, the 
synthetic intermediate 3 was prepared. Nα Fmoc-protected Lys derivative 1 was reacted 
with an activated SA N-hydroxysuccinimide ester 2
4(h)
 to afford 
Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH 3 in 80% yield (Scheme 5).  
 
 
 
  
 
Scheme 5. Synthesis of Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH 3. 
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The resulting Lys derivative 3 and Fmoc-miniPEG
™
 were successively incorporated by 
standard Fmoc SPPS protocol using the DIC/HOBt system on a NovaSyn
®
 TGR resin. 
After coupling of the Fmoc-Gly-SEAlide-OH 8
9(h)
 using 
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate 
(HATU) and N,N-diisopropylethylamine (DIPEA), the DIC/HOBt system was used to 
incorporate Fmoc-miniPEG
™
. The resulting resins 6a-c were reacted with FTC, and the 
resin-bound SEAL-tags were finally treated with TFA-Et3SiH-H2O (95:2.5:2.5 [v/v]) to 
generate the desired SEAL-tag 7a-c. 
 
 
 
 
12 
 
 
  
 
Scheme 6. Synthesis of SEAL-tag 7a-c. 
13 
 
In Scheme 7, I described a synthetic strategy of SEAL-tag 13 for labeling of COX-1. 
SEAL-tag 13 was synthesized in a manner similar to that employed for the synthesis of 
SEAL-tag 7a-c. In this strategy, N ivDde-protected Lys derivative 917 was employed 
as synthetic material, because ivDde group was stable under standard Fmoc SPPS 
conditions, whereas ivDde group was selectively removed by treatment with 2% (v/v) 
hydrazine hydrate in DMF.
18
 I expected that the use of ivDde-protected Lys derivative 
would enable ready introduction of various bioactive ligands into the SEAL-tag in late 
step of the synthesis. 
ivDde-protected Lys derivative 9 was successively incorporated by standard Fmoc 
SPPS protocol using the DIC/HOBt system on a NovaSyn
®
 TGR resin. After coupling 
of the Fmoc-Gly-SEAlide-OH 8 using HATU and DIPEA, the DIC/HOBt system was 
used to incorporate Fmoc-miniPEG
™
 and biotin. The resulting resin was treated with 
2% (v/v) hydrazine hydrate in DMF, and indomethacin was condensed on the resulting 
ivDde-deprotected resin using the DIC/HOBt protocol. The resin-bound SEAL-tag was 
finally treated with TFA-Et3SiH-H2O (95:2.5:2.5 [v/v]) to generate the desired 
SEAL-tag 13. 
  
14 
 
 
Scheme 7. Synthesis of SEAL-tag 13. 
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1. 3 Conclusion 
 
I developed a novel affinity-based labeling reagent, SEAlide-based labeling tag 
(SEAL-tag). The SEAL-tag is readily prepared using standard Fmoc-based solid-phase 
protocol. For the labeling of hCA and COX-1, facile synthesis of the SEAL-tag bearing 
benzenesulfonamide (for hCA) or indomethacin (for COX-1) as a specific ligand was 
achieved. 
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Chapter 2 Labeling of target proteins using SEAL-tag 
 
2.1 Optimization of the structure of the SEAL-tag 
 
Initially, I determined a suitable length of the mini-PEG linker for the most efficient 
labeling of hCA1. FTC-modified SEAL-tags 7a-c bearing various repeats of the 
mini-PEG unit were prepared and incubated with commercially available hCA1 (10 
M) at 37 ºC in 50 mM HEPES buffer (pH 7.2).4(h) Aliquots of the different reaction 
mixtures containing FTC-labeled hCA1 were sampled after 72 h incubation and 
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by fluorescence gel imaging (FI). So far examined here, incubation using 7a 
(n=0 for the chain length) afforded maximal fluorescence intensity (Figure 5b, lane 1). 
However, this is not always the case for other protein materials, because suitable fitting 
of SEAL-tags with ligand-binding cavities is crucial for efficient labeling. 
To monitor the progress of hCA1 labeling, SEAL-tag 7a was incubated with hCA1 at 37 
ºC in 50 mM HEPES buffer (pH 7.2) and aliquots of different reaction mixture 
containing FTC-labeled hCA1 were collected every 24 h. The collected samples were 
analyzed by SDS-PAGE followed by FI. The results revealed that the labeling of hCA1 
with 7a reached a plateau within 48 h (Figure 5c). 
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Figure 5. Optimization of the structure of the SEAL-tag. (a) Chemical structures of 
SEAL-tag 7a-7c. (b) SDS-PAGE analysis of the hCA1-labeling with SEAL-tag 7a-7c. 
The gel was analyzed by in-gel fluorescence imaging (left, FL) and stained using silver 
staining protocol (right, silver stain). Reaction conditions: purified hCA1 (10 M) was 
incubated with SEAL-tag 7a, 7b, or 7c (100 M) in 50 mM HEPES buffer (pH 7.2) at 
37 °C for 72 h. (c) Time-course analysis of the hCA1 labeling with SEAL-tag 7a using 
SDS-PAGE. The gel was analyzed by in-gel fluorescence imaging (left, FL) and stained 
using silver staining protocol (right, silver stain). Reaction conditions: purified hCA1 
(10 M) was incubated with SEAL-tag 7a in 50 mM HEPES buffer (pH 7.2) at 37 °C 
for the specified time. (M: molecular-weight marker) 
 
  
(b) 
(c) 
(a) 
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I also established whether SEAL-tags site-specifically labeled nucleophilic amino acids. 
In this experiment, a dual-modified SEAL-tag 14 containing biotin and FTC group was 
used for labeling of hCA1, because the labeled and unlabeled hCA1 proteins could be 
individually detected by SDS-PAGE (Figure 6). Purified hCA1 (10 M) was incubated 
with SEAL-tag 14 (100 M) at 37 ºC in 50 mM HEPES buffer (pH 7.2) for 48 h. The 
labeled hCA1 was isolated from protein mixture containing unlabeled hCA1 by 
SDS-PAGE, and digested by trypsin in the gel.
19
 The resulting digested peptide 
fragments were extracted from the gel and analyzed by nanoLC-MS/MS. The results 
revealed that Lys137 (Figure 7c), which is located in close proximity to the 
ligand-binding site, was selectively labeled with the reporter (Figure 7b).
12(a)
 
 
 
 
 
Figure 6. Chemical structure of SEAL-tag 14, bearing FTC and biotin as a reporter. 
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Figure 7. Mass spectral analysis of the labeling site of hCA1. (a) The primary sequence 
of hCA1. (b) Crystal structure of hCA1 complexed with 
3-actoxymercuri-4-aminobenzenesulfonamide (PDB ID: 1CZM). The amino acid (Lys 
137) modified by SEAL-tag 14 is highlighted by a colored stick model. (c) 
nanoLC-MS/MS analysis of the fragment labeled at Lys137. 
 
(a) (b) 
(c) 
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2.2 Selective labeling of target proteins 
 
Subsequently, I evaluated the target labeling using SEAL-tags. A protein mixture 
containing hCA1, enolase,
20
 ovalbumin (OVA)
21
 and glutathione S-transferase (GST)
22
 
(10 M each) was incubated with SEAL-tag 7a (100 M) at 37 °C in 50 mM HEPES 
buffer (pH 7.2) for 48 h. Excess amount of the labeling reagent in the samples was 
removed by ultrafiltration,
23
 and the resulting samples were analyzed by SDS-PAGE 
followed by FI. The analysis showed that a strong fluorescent band corresponding to the 
FTC-labeled hCA1was presented (Figure 8b). These results therefore demonstrated that 
I could achieve the selective labeling of a target protein in a protein mixture using the 
SEAL-tag system, while leaving the none-target protein unchanged. 
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Figure 8. Selective labeling of hCA1 in a protein mixture. (a) Chemical structure of 
SEAL-tag 7a. (b) SDS-PAGE analysis of the selective labeling of hCA1 with SEAL-tag 
7a in a protein mixture consisting of four different proteins. The gel was analyzed by 
in-gel fluorescence imaging (left, FL) and stained using silver staining protocol (right, 
silver stain). Reaction conditions: SEAL-tag 7a (100 M) was incubated in 50 mM 
HEPES buffer (pH 7.2) containing four different proteins (10 M each; enolase, GST, 
hCA1, and OVA) at 37 °C for 48 h. 
 
  
(a) 
(b) 
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To verify that the versatility of the selective labeling of target proteins using the 
SEAL-tag resulted, I attempted to label COX-1 in a protein mixture using SEAL-tag 
containing indomethacin (IM) as a specific ligand for COX-1. Three proteins consisting 
of bovine serum albumin (BSA),
24
 COX-1, and enolase (1.4 M each) with SEAL-tag 
13 (14 M) were incubated in 80 mM Tris·HCl buffer (pH 8.0) at 4 °C for 48 h. Notably, 
this experiment was conducted at 4 °C because of instability of COX-1 at 37 °C in 
aqueous buffer without a stabilizer.
25
 The incubation mixture was subsequently 
analyzed by SDS-PAGE, which revealed the presence of a single biotin-labeled protein 
using a streptavidin-horseradish peroxidase conjugate (SAv-HRP).  Figure 9b shows a 
single band corresponding biotinylated-COX-1 that was detected at approximately 70 
kDa. These results showed that the SEAL-tags could be used for the various target 
proteins of bioactive compound labeling in protein mixtures. 
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Figure 9. Selective labeling of COX-1 in a protein mixture. (a) Chemical structure of 
SEAL-tag 13, bearing indomethacin (IM) as a specific ligand for COX-1 labeling. (b) 
Western blotting analysis of biotin-labeled protein using the biotin–streptavidin-HRP 
method (left, SAv-HRP), and all proteins in the gel were visualized by silver staining 
(right, silver stain). Reaction conditions: SEAL-tag 13 (14 M) was incubated in 80 
mM Tris·HCl buffer (pH 8.0) containing three different proteins (1.4 M each; BSA, 
COX-1, and enolase) at 4 °C for 48 h. 
 
 
  
(a) 
(b) 
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2.3 Selective labeling of endogenous hCA  
 
We also investigated the application of this strategy for the labeling of endogenous hCA 
in human red blood cells (RBCs) or the cell lysate using the SEAL-tag.
11(b)
 
First, we performed the selective labeling of hCA in the lysate of RBS. The lysate of 
RBC was incubated with SEAL-tag 14 at 37 ºC for 48 h. The incubation mixture was 
analyzed by SDS-PAGE followed by detection with SAv-HRP, which revealed the 
presence of a single band corresponding to biotin-modified protein. Figure 10b shows 
the single band corresponding biotin-modified hCA at approximately 29 kDa. These 
results showed that the endogenous target protein that was present in minute amounts in 
cells could be labeled and visualized using the SEAL-tag. 
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Figure 10. Selective labeling of hCA in lysate of RBC. (a) Chemical structure of 
SEAL-tag 14. (b) SDS-PAGE analysis of the FTC-labeled protein in RBC lysate with 
SEAL-tag 14. The gel was analyzed by in-gel fluorescence imaging (left, FL) and 
stained using silver staining protocol (right, silver stain). Reaction conditions: 
SEAL-tag 14 (100 M) was incubated in RBC lysate diluted with 50 mM HEPES 
buffer (pH 7.2) at 37 °C for 48 h. 
 
  
(a) 
(b) 
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Next, I designed and synthesized a new SEAL-tag for the labeling of a target protein in 
cells. In general, low-molecular-weight hydrophobic compounds could more efficiently 
permeate through cell membranes than high-molecule-weight hydrophilic compounds.
26
 
With this in mind, we designed and synthesized SEAL-tag 15 to provide improved 
membrane permeability and enhanced labeling efficiency towards intracellular proteins 
compared with SEAL-tag 7a. Notably, the charactristics of SEAL-tag 15 are (1) a lower 
molecular weight than SEAL-tag 7a; and (2) the absence of hydrophilic mini-PEG 
linker (Figure 11a). Using SEAL-tag 15, I also attempted to label hCA in RBCs. RBCs 
with SEAL-tag 15 were incubated in HEPES-buffered saline (HBS) for 48 h at 37 °C, 
before being washed three times with fresh HBS. The resulting RBCs were lysed and 
the resulting lysate was centrifuged for separating soluble fraction. The soluble fraction 
was collected and analyzed by SDS-PAGE followed by detection with SAv-HRP. A 
single band corresponding to biotinylated-hCA at approximately 37 kDa was detected 
(Figure 11b lane 1). 
In the presence of ethoxyzolamide (EZA), which is a strong binder against the 
SA-binding pocket of hCA, I did not notably observe the SA-dependent labeling of hCA 
(Figure 11b lane 2). These results therefore demonstrated that the use of hydrophobic 
and low molecular weight SEAL-tag bearing a SA ligand could be used as an efficient 
strategy for the intracellular labeling of hCA in a ligand-dependent fashion.   
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Figure 11. Selective labeling of hCA in RBCs. (a) Chemical structure of SEAL-tag 15. 
(b) Western blotting analysis of the biotin-labeled protein in RBCs using the 
biotin–streptavidin-HRP method (left, SAv-HRP), and all proteins in the gel were 
visualized by silver staining (right, silver stain). The band with the single asterisk (*) 
correspond to hCA, whereas those with the double asterisk (**) correspond to 
non-specific detected with streptavidin-HRP band. Reaction conditions: RBCs and 
SEAL-tag 15 (100 M) were incubated in HEPES-buffered saline (HBS, pH 7.2) at 
37 °C for 48 h. 
  
(a) 
(b) 
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2.4 Elucidation of the mechanism of this SEAL-mediated labeling process 
 
I examined whether N–S acyl transfer of SEAlide unit is necessary for protein labeling 
process using the SEAL-tag 16 bearing S-protected SEAlide unit. Mixture of COX-1 
and SEAL-tag 13 or 16 was subjected to labeling reaction in 80 mM Tris·HCl buffer 
(pH 8.0) for 48 h at 4 °C and the reaction liquids were collected and analyzed by 
SDS-PAGE. Using SEAL-tag 13 for the labeling reaction, I detected a single band 
corresponding to biotinylated-COX-1 at approximately 70 kDa. On the other hand, no 
band was detected using SEAL-tag 16, and thereby these results indicated that the N–S 
acyl transfer reaction was a critical step in the labeling process of proteins. 
 
 
 
 
 
 
 
Figure 12. Elucidation of the mechanism for the SEAL-tag-mediated labeling of the 
protein. (a) Chemical structure of SEAL-tag 16. (b) Western blotting analysis of 
biotin-labeled COX-1, detected with streptavidin-HRP (left, SAv-HRP), anti-COX-1 
antibody (right, anti-COX1). Reaction conditions: SEAL-tag 13 or 16 (14 M) was 
incubated in 80 mM Tris·HCl buffer (pH 8.0) containing purified-COX-1 (1.4 M) at 
4 °C for 48 h. 
 
  
(a) 
(b) 
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Finally, I attempted to address the issue of whether the surface of the protein acts as an 
acid-base cluster catalyst to enhance the N–S acyl transfer reaction. In the presence of a 
large amount of nucleophile, I confirmed that SEAlide remained intact in the absence of 
an acid-base catalyst in an acylation reaction. The SEAL-tag (10 M) was incubated 
with butylamine (1 M) in 50 mM HEPES buffer (ph 7.2) at 37 °C and aliquots of 
incubated solution were collected every 24 h and analyzed by high performance liquid 
chromatography (HPLC). The analysis showed that the SEAL-tag did not react with 
amine. Although I have not yet collected any direct evidence to suggest that the N–S 
acyl transfer reaction is accelerated by acid-base residues on protein surfaces, I have 
collected the following anecdotal evidence: (1) SEAL-tag 15 remained intact in the 
presence of a large amount of amine in HEPES buffer. (2) SEAL-tags immobilized on 
protein surfaces in a ligand-dependent manner could modify Lys--amino groups, which 
would present themselves in a stoichiometric ratio relative to the SEAL-tag under the 
labeling conditions. 
 
 
 
Figure 13. HPLC analysis of the SEAL-tag 15 (〇, 10 M) with butylamine (1 M) in 
50 mM HEPES buffer (pH 7.2) at 37 ºC for 5 min > (left), 24 h (middle), or 48 h (right) 
of incubation. × denotes oxidated SEAL-tag 15; however, the aminolysis product was 
not detected. 
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2. 5 Conclusion 
 
Ligand-dependent selective labeling of hCA in a protein mixture or human red blood 
cells was achieved. NanoLC-MS/MS analysis of the labeled hCA revealed that 
modification site-specifically occurred at Lys137 located in close proximity to the 
ligand-binding site. Furthermore, the SEAL-tag bearing indomethacin as specific ligand 
for COX-1 also specifically modified COX-1 in a protein mixture. These results clearly 
indicated that the newly developed SEAL-tag served as ligand-mediated labeling 
reagent. 
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Chapter 3 Conclusions 
 
On the basis of the unique chemical nature of the SEAlide unit, in that the 
electrophilically inert amide-type SEAlide is converted to the corresponding active 
thioester-type SEAlide through N-S acyl transfer catalyzed by phosphate salts as a 
general acid-base catalyst, the SEAlide-based labeling tag (SEAL-tag) as a novel 
ligand-mediated-labeling reagent was developed. Synthesis of the inert amide-type 
SEAL-tag was efficiently effected by incorporation of the SEAlide moiety into the 
SEAL-tag using Fmoc-SPPS protocols. Ligand-mediated concentration of the SEAL-tag 
on target proteins with the inert amide part activated through N-S acyl transfer possibly 
catalyzed by the acid-base cluster on the surface of the target proteins enabled the 
specific labeling of the target protein. As model cases, specific labeling of hCA and 
COX-1 using the SEAL-tags-bearing ligands specific for the target proteins was 
achieved. 
There remains an unsolved issue as to whether the acid-base cluster on the protein 
surface is actually involved in the activation of the inert amide-type SEAlide unit, 
whereas indirect evidence for such the involvement was obtained. At this stage, the 
direct evidence rationalizing the activation has yet to be acquired. 
In addition to research to obtain the direct evidence, identification of a target protein 
using a SEAL-tag bearing a target-unknown ligand should be conducted to expand the 
utility of the SEAL-tag in chemical biology fields. 
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General Methods 
 
All reactions of small molecules were carried out under a positive presser of argon. For 
column chromatography, silica Gel 60 N (sperical, neutral, Kanto Chemical Co. Inc.) 
was employed. Thin layer chromatography was performed on precoated plates (0.25 nm, 
silica gel Merck Kiesegel 60F245). Mass spectra were recorded on a Waters 
MICROMASS
®
 LCT PRIME™ (ESI-TOF) or a Bruker Esquire2000T (ESI-Ion trap). 
NMR spectra were recoded using a Bruker AV400N at 400 MHz frequency for 
1
H and a 
JEOL JNM-AL300 at 75 MHz frequency for 
13
C in methanol-d4. Chemical shifts are 
calibrated to the solvent signal. For HPLC separations, a Cosmosil 5C18-AR-II 
analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1 mL/min) or a 5C18-AR-II 
preparative column (Nacalai Tesque, 20 × 250 mm, flow rate 10 mL/min) was 
employed, and eluting products were detected by UV at 220 nm. A solvent system 
consisting of 0.1% (v/v) TFA aqueous solution (solvent A) and 0.1% (v/v) TFA in 
MeCN (solvent B) was used for HPLC elution. Fluorescence and chemiluminescent 
signals were detected with LAS-4000mini (Fujifilm). 
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Chapter 1 
 
Synthetic of SEAL-tags 
SEAL-tags were prepared by Fmoc-solid phase protocols using Fmoc-miniPEG™, 
Fmoc-Gly-SEAlide-OH,
9(h)
 Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH (for hCA1 labelling) 
and Fmoc-L-Lys(ivDde)-OH (for COX-1 labelling). 
 
 
Synthesis of Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH (3) 
 
 
 
To a stirred solution of Fmoc-L-Lys-OH (346 mg, 0.940 mmol) in DMF (2.5 mL) were 
added 4-sulfamoylbenzoic acid N-hydroxysuccinimide ester (365 mg, 1.22 mmol) and 
DIPEA (486 L, 2.82 mmol), and the reaction mixture was stirred for 3.5 h. The 
mixture was concentrated in vacuo, and the obtained residue was dissolved in EtOAc. 
The organic layer was washed with 5% (w/v) aqueous citric acid, H2O and brine, dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by column 
chromatography (CHCl3/MeOH = 9:1) and 427 mg of 
Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH (3) (0.754 mmol, 80%) was obtained as a white 
powder: []19D 2.79 (c 0.64, CH3OH); 1H NMR (400 MHz, CD3OD) = 1.45-1.58 (m, 
2H), 1.58-1.81 (m. 3H), 1.91 (m, 1H), 3.42 (t, J = 7.0 Hz, 2H), 4.18 (dd, J = 4.4, 9.2 Hz, 
1H), 4.24 (t, J = 6.8 Hz, 1H), 4.34 (dd, J = 6.8, 10.7 Hz, 1H), 4.39 (dd, J = 6.8, 10.7 Hz, 
1H), 7.31 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 7.0 Hz, 2H), 7.68 (d, J = 7.6 Hz, 2H), 7.70 (d, J 
= 7.6 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.98 (d, J = 8.8 Hz, 
2H), 13C NMR (75 MHz, CD3OD):  = 24.4, 29.9, 32.3, 40.9, 55.2, 67.9, 120.9, 126.2, 
127.3, 128.1, 128.8, 129.0, 142.6, 145.2, 145.3, 147.6, 158.7, 168.8, 175.9; HRMS 
(ESI-TOF) m/z calcd for C28H29N3O7NaS ([M+Na]
+
) 574.1624, found 574.1625) 
 
 
Synthesis of SEAlide-based Labeling Tag (SEAL-tag) (7a) 
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Synthesis of SEAL-tag 7a was performed by using Fmoc-based solid-phase protocols 
on NovaSyn
®
 TGR resin (loading: 0.22 mmol/g, 45 mg, 0.010 mmol). Coupling of 
Fmoc-L-Lys(4-sulfamoyl-benzoyl)-OH (17 mg, 0.030 mmol) with the aid of DIC (4.6 
L, 0.030 mmol)/HOBt·H2O (4.6 mg, 0.030 mmol) in DMF was performed, and 
treatment with 20% (v/v) piperidine in DMF was used for the removal of Fmoc 
protection to give a resin. Fmoc-Gly-SEAlide-OH (1.4 mg, 0.020 mmol) was coupled 
on the resulting resin by HATU (7.2 mg, 0.019 mmol) and DIPEA (3.3 L, 0.019 mmol) 
in DMF at room temperature in DMF for 2 h. After deprotection of Fmoc group with 
20% (v/v) piperidine in DMF, coupling of Fmoc-mini-PEGTM (12 mg, 0.030 mmol) in 
DMF were conducted by Fmoc-based solid-phase protocols. To obtained resin were 
added fluorescein-5-isothiocyanate (FITC, 9.7 mg, 0.025 mmol) and DIPEA (43 L, 
0.025 mmol) in DMF, and the reaction was performed for 2 h. The resulting completed 
resin was treated with TFA-TES-H2O (95:2.5:2.5, 3.3 mL) for 2h. After filtration of the 
resin, the filtrate was concentrated to provide the crude product. The obtained crude 
product was purified by preparative HPLC to yield SEAL 1 (1.51 mg, 14%, an yellow 
lyophilized powder). Analytical HPLC conditions: gradient of solvent B in solvent A, 
10-60% over 30 min. Retention time = 20.9 min. Preparative HPLC conditions: linear 
gradient of solvent B in solvent A, 30 to 40% over 30 min. MS (ESI-TOF) m/z calcd for 
C51H54N8O14S3 ([M+H]
+
): 1099.3, found 1099.6. 
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Synthesis of SEAL-tag (7b) 
 
 
 
SEAL-tag 7b was synthesized in a manner similar to that employed in the synthesis of 
SEAL-tag 7a. NovaSyn® TGR resin (loading: 0.22 mmol/g, 45.0 mg, 0.01 mmol) was 
used to yield SEAL-tag 7b (2.85 mg, 23%, an yellow lyophilized powder). Analytical 
HPLC conditions: gradient of solvent B in solvent A, 10-60% over 30 min. Retention 
time = 20.7 min. Preparative HPLC conditions: linear gradient of solvent B in solvent A, 
30 to 40% over 30 min. MS (ESI-TOF) m/z calcd for C57H65N9O17S3  ([M+H]+): 
1244.4, found 1244.8. 
 
 
Synthesis of SEAL-tag (7c) 
 
 
 
SEAL-tag 7c was synthesized in a manner similar to that employed in the synthesis of 
SEAL-tag 7a. NovaSyn® TGR resin (loading: 0.22 mmol/g, 45.0 mg, 0.01 mmol) was 
used to yield SEAL 7c (2.90 mg, 21%, an yellow lyophilized powder). Analytical HPLC 
conditions: gradient of solvent B in solvent A, 10-60% over 30 min. Retention time = 
20.4 min. Preparative HPLC conditions: linear gradient of solvent B in solvent A, 29 to 
39% over 30 min. MS (ESI-TOF) m/z calcd for C63H76N10O20S3 ([M+H]
+
): 1389.5, 
found 1389.9. 
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Synthesis of SEAL-tag (13) 
 
 
 
SEAL-tag 13 was synthesized in a manner similar to that employed in the synthesis of 
SEAL-tag 7a on NovaSyn® TGR resin (loading: 0.25 mmol/g, 200 mg, 0.050 mmol). 
Coupling of Fmoc-L-Lys(ivDde)-OH (86 mg,  0.15 mmol) with the aid of DIC (23 L, 
0.15 mmol)/HOBt·H2O (20 mg, 0.15 mmol) in DMF was performed, and treatment 
with 20% (v/v) piperidine in DMF was used for the removal of Fmoc protection to give 
a resin. Fmoc-Gly-SEAlide-OH (72 mg, 0.10 mmol) was coupled on the resulting resin 
by using HATU (36 mg, 0.095 mmol) and DIPEA (17 L, 0.095 mmol) in DMF at room 
temperature for 2 h. After deprotection of Fmoc group of the resulting resin with 20% 
(v/v) piperidine in DMF, stepwise coupling of Fmoc-miniPEG™ (58 mg, 0.15 mmol) in 
DMF and biotin (61 mg, 0.25 mmol) in DMF-DMSO (3:1 (v/v)) were conducted by 
Fmoc-based solid-phase protocols. The ivDde group on the Lys residue was removed by 
treatment with 2% (v/v) hydrazine monohydrate in DMF for 17 h, and the generated 
amine and indomethacin (54 mg, 0.15 mmol) in DMF were conducted by Fmoc-based 
solid-phase protocols. The resulting completed resin was treated with TFA-TES-H2O 
(95:2.5:2.5, 16 mL) for 2h. After filtration of the resin, the filtrate was concentrated to 
provide a crude product. The obtained crude product was purified by preparative HPLC 
to yield SEAL-tag 13 (0.38 mg, 0.6%, a white lyophilized powder). Analytical HPLC 
conditions: gradient of solvent B in solvent A, 10-60% over 30 min. Retention time = 
25.7 min. Preparative HPLC conditions: linear gradient of solvent B in solvent A, 38 to 
48% over 30 min. MS (ESI-TOF) m/z calcd for C70H99ClN12O20S2 ([M+H]
+
): 1527.6, 
found: 1527.9. 
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Synthesis of SEAL-tag (14) 
 
 
 
SEAL-tag 14 was synthesized in a manner similar to that employed in the 
synthesis of SEAL-tag 13. NovaSyn® TGR resin (loading: 0.22 mmol/g, 227 
mg, 0.050 mmol) was used to yield SEAL 14 (22.0 mg, 28%, an yellow 
lyophilized powder).Analytical HPLC conditions: gradient of solvent B in 
solvent A, 10-60% over 30 min. Retention time = 19.5 min. Preparative 
HPLC conditions: linear gradient of solvent B in solvent A, 28 to 38% over 30 
min. MS (ESI-TOF) m/z calcd for C79H102N14O23S3 ([M+2H]2+): 799.6, found 
799.5. 
 
 
Synthesis of SEAL-tag (15) 
 
 
 
SEAL-tag 15 was synthesized in a manner similar to that employed in the synthesis of 
SEAL-tag 7a. NovaSyn® TGR resin (loading: 0.24 mmol/g, 208 mg, 0.050 
mmol) was used to yield SEAL 6 (13 mg, 33%, a white lyophilized powder). 
Analytical HPLC conditions: gradient of solvent B in solvent A, 10-60% over 
30 min. Retention time = 16.8 min. Preparative HPLC conditions: linear 
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gradient of solvent B in solvent A, 23 to 33% over 30 min. MS (ESI-TOF) m/z 
calcd for C34H46N8O8S3 ([M+H]+):791.3, found: 791.1. 
 
 
Synthesis of SEAL-tag (16) 
 
 
 
To a solution of SEAL-tag 13 (10.6 mg, 6.87 mol) in DMF was added MeI (69.0 L, 
1.11 mmol) and DIPEA (69.0 L, 6.87 mol) with stirring at room temperature for 1 h. 
The reaction mixture was purified by preparative HPLC to yield SEAL-tag 16 (4.43 mg, 
42%, a white lyophilized powder). Analytical HPLC conditions: gradient of solvent B in 
solvent A, 10-60% over 30 min. Retention time = 25.9 min. Preparative HPLC 
conditions: linear gradient of solvent B in solvent A, 35 to 49% over 30 min. MS (ESI) 
m/z calcd for C71H101ClN12O20S2  ([M+H]+): 1541.7, found 1541.7. 
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Chapter 2 
 
Optimization of the structure of SEAL-tags 
 
Purified human carbonic anhydrase 1 (hCA1) was purchased from SIGMA-Aldrich and 
used without further purification. The hCA1 (10 M) with 7a-c (100 M) was 
incubated at 37 °C in 50 mM HEPES buffer (pH 7.2). At every 24 h, the reaction 
aliquots were subjected to ultrafiltration (14,000 g, 15 min, himac CT 15RE (Hitachi 
Koki Co., Ltd.)) using Amicon
®
 Ultra-0.5 Centrifugal Filter Devices (Merck Millipore) 
and the concentrate was mixed with the same volume of 2×SDS sample loading buffer 
followed by heating at 100 °C for 5 min. The heated reaction mixtures were analyzed 
using SDS-PAGE in 14% in polyacrylamide gels. For the chemiluminescence imaging 
of the biotinylated proteins, the proteins were transferred to Amersham Hybond-P 
PVDF Membrane (GE Healthcare) and detected with a streptavidin-horseradish 
peroxidase conjugate (SAv-HRP, GE Healthcare) and ECL plus Western Blotting 
Detection System (GE Healthcare).  For silver staining of all proteins, proteins in a gel 
were stained with Silver Stain KANTOⅢ (KANTO CHEMICAL CO., INC.). 
To determaine that the labelling of hCA1 was site-specifically occurred, purified hCA1 
(10 M) was labelled using 14 (100 M) according to the method described above. The 
labelled hCA1 was subjected to SDS-PAGE in 14% in polyacrylamide gel and stained 
with CBB Stain One (Nacalai tesqe). The gel containing of the labelled hCA1 with 
trypsin was incubated at 37 °C in Tris·HCl buffer (pH 8.0) for 20 h. The digested 
labelled-hCA1 was analyzed on nanoLC-MS/MS. 
LC: UltiMate 3000 RSLCnano system (Thermo Fisher Scientific Inc.) 
MS: Orbital Elite (Thermo Fisher Scientific Inc.) 
Column: Acclaim PepMap RSLC Nano Column (75 m×15 cm, Thermo Fisher 
Scientific Inc.) 
Solvent A: 0.1% formic acid aq.; solvent B 0.08% formic acid/80% MeCN aq. 
 
 
Selective labeling of hCA1 in a protein mixture 
 
A protein mixture containing of enolase, GST, hCA1 and OVA (10 M each, purchased 
from SIGMA) with 7a (100 M) was incubated in 50 mM HEPES buffer (pH 7.2) at 
37 °C for 48 h. The reaction mixture was subjected to ultrafiltration and the 
concentrated mixture was blended with the same volume of 2×SDS sample loading 
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buffer followed by heating at 100 °C for 5 min. The heated samples were applied to 
14% SDS-PAGE, and analyzed by in-gel fluorescence imaging and silver-staining. 
 
 
Selective labeling of COX-1 in a protein mixture 
 
As a protein mixture, BSA purchased from SIGMA, cyclooxygenase 1 (COX-1) 
purchased from Cayman Chemical and enolase (1.4 M each) was used. The mixture of 
proteins with 13 was incubated in 80 mM Tris·HCl buffer (pH 8.0) at 4 °C for 48 h. The 
reaction mixture was analyzed using SDS-PAGE in 10% polyacrylamide gels followed 
by chemiluminescence imaging according to the methods described above. For silver 
staining of all proteins, proteins in a gel were stained with Silver Stain KANTOⅢ. 
 
 
Selective labeling of endogenous hCA in RBC lysate 
 
Human red blood cells (hRBCs) were purchased from BizCom Japan, Inc., and purified 
by the use of a centrifugation (3,000 g, 15 min). Purified hRBCs were resuspended in 
50 mM HEPES buffer (pH 7.2) and lysed by sonication for 15 min at 0 ºC. The resulting 
lysate and 14 was incubated with at 37 °C for 48 h. The reaction mixture was subjected 
to ultrafiltration and the concentrated mixture was blended with the same volume of 2×
SDS sample loading buffer followed by heating at 100 °C for 5 min. The heated 
samples were applied to 14% SDS-PAGE and analyzed by in-gel fluorescence imaging 
and silver-staining. 
 
 
Selective labeling of endogenous hCA in RBCs 
 
hRBCs purified by the use of a centrifugation (3,000 g, 15 min). Purified hRBCs were 
resuspended in HEPES-buffered saline (HBS) and incubated with 15 (200 M) in the 
absence or presence of ethoxyzolamide (EZA, 2 mM) at 37 °C for 48 h. The incubated 
hRBCs were washed three times with HBS and lysed by sonication. The resulting lysate 
was centrifuged (12,000 g, 30 min) and the resulting supernatant was collected and 
separated with 5 by the use of ultrafiltration. The resulting mixture was analyzed using 
SDS-PAGE in 10% polyacrylamide gels followed by chemiluminescence imaging 
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according to the methods described above. For silver staining of all proteins, proteins in 
a gel were stained with Silver Stain KANTOⅢ. 
 
 
Elucidation of a mechanism of the labeling using a SEAL-tag 
 
Purified COX-1 (1.4 M) was incubated with 13 or 16 (14 M) in 80 mM Tris·HCl 
buffer at 4 °C for 48 h. The reaction mixtures were subjected to ultrafiltration followed 
by SDS-PAGE analysis. The biotinylated COX-1 was detected with SAv-HRP using 
ECL plus Western Blotting Detection System.  
The immunodetection of COX-1 was accomplished with COX-1 monoclonal antibody 
and anti-mouse IgG-HRP conjugate (both Santa Cruz Biotechnology). 
To demonstrate of the stability of 15, butylamine (1 M) and 15 (10 M) were incubated 
in 50 mM HEPES buffer (pH 7.2) at 37 °C. At every 24 h, reaction aliquots containing 
15 were collected and analyzed by HPLC. Analytical HPLC conditions: gradient 
of solvent B in solvent A, 10-60% over 30 min.   
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